Tibulizumab
As of the edition of 20 October 2026, Tibulizumab is an antibody: in active development; acts on IL17A and TNFSF13B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 6, 1 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Eye; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Tibulizumab.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 6 |